Onconic Therapeutics hit the upper price limit in early trading on the 10th. Investor sentiment appears to have surged on news that preclinical results for its investigational pancreatic cancer drug candidate were published in an international journal.
At 9:20 a.m. that day, shares of Onconic Therapeutics on the KOSDAQ market jumped 29.75% (4,850 won) from the previous trading day to 21,150 won, racing to the upper price limit (the top of the daily price band).
This came after the company that morning said preclinical results in pancreatic cancer for the next-generation synthetic lethality dual-target anticancer drug candidate "Nesuparib (JPI-547)" were published in the SCI-level international journal IJBS (International Journal of Biological Sciences).
IJBS is known as an authoritative journal that ranks in the top 10% of SCI in the fields of life science, molecular biology, and biochemistry. The study was led by Professor Oh Do-yeon's research team in the Division of Oncology at the College of Medicine of Seoul National University.